My mental model of targeted therapies:
1. Convex dose response (double the dose, get less than double response)
2. Concave resistance onset (cut the dose in half, reduce the resistance by more than half)
My mental model of targeted therapies:
1. Convex dose response (double the dose, get less than double response)
2. Concave resistance onset (cut the dose in half, reduce the resistance by more than half)
This week in Math Onco ~
Very cool artwork from Paul Newton, Matthew Giles
Based on the paper: Reinforcement learning for chemotherapy scheduling in a stochastic tumor evolution model published in Physical Review E
Today’s @mathonco research in progress is from #AndersonLab member Daniel Camacho. Giving his 1st RIP on his 1 year @MoffittNews anniversary discussing; Economic calculation and mathematical oncology: rethinking prediction through the Austrian school.
First time visiting #Purdue for the #SIAM Great Lakes Section Meeting! A great selection of talks on MathBio, SciML, and Complex Systems - I spoke about agentic AI for autonomous modeling and simulation in biological systems - joint work with @mathoncbro!
purdue.edu/science/events/gl…
Check out the new initiation from Bulletin of Mathematical Biology called MathBioNexus.
Live seminars, the next one entitled "Cells, bureaucracy and corruption" by Fred Adler
cassyni.com/events/S1zv5xP1X…
I wasn't expecting agentic AI to have such a big impact on scientific manuscript rate, mainly because we are still so early. Most (?) academics still have not used AI agents.
After 95 straight days with an average high temperature of 91°, Tampa's average high dropped to 90° today. Average high will continue to slowly drop until it reaches 71° on January 4th. Baby steps to cooler weather in #Florida
.@nancykgillis & I just published a Spotlight piece, highlighting Armel Batchi-Bouyou, Kelly Bolton et. al's interesting work on predictive modeling of clonal hematopoiesis
Original research: sciencedirect.com/science/ar…
This is a really neat project! It turns out ALCL is a plausible candidate for evolutionary therapy due to an exceedingly high cost of resistance to ALK inhibitors
Spotlight: Antifragility in Cancer!
@AmyEPomeroy & @ac_palmer wrote a Spotlight highlighting our recent mansucript on antifragile therapy dosing strategies in Cancer Research: